

FRIULCHEM SIGNS AN AGREEMENT WITH AN ITALIAN PHARMACEUTICAL COMPANY - A PROVIDER OF INNOVATIVE AND RELIABLE SERVICES TO PHARMACISTS AND PHARMACEUTICAL COMPANIES - FOR THE DEVELOPMENT AND EXCLUSIVE SUPPLY OF PET SUPPLEMENTS ON FC-CUBES TECHNOLOGY.

Milan, 09 December 2021 - **Friulchem S.p.A. (EGM: FCM)**, an innovative SME and one of the main Italian players operating at international level in R&D and contract manufacturing (CDMO) of semi-finished and finished products containing active pharmaceutical ingredients, food supplements, with specialisation in drug delivery for the veterinary sector, announces the signing of an agreement with an Italian pharmaceutical company for the development and supply of pet supplements with proprietary technology FC-Cubes.

The agreement, with an initial duration of 5 years and with an important strategic value, confirms Friulchem's role as a reliable partner in offering quality solutions and products in the pet market, which is constantly growing. The agreement will help increase turnover and margins, thus consolidating the company's role in the Italian veterinary market.

Disma Giovanni Mazzola, CEO of Friulchem, commented: "We are proud to have signed this agreement with a major Italian pharmaceutical company. This partnership once again confirms our willingness to expand at a national level and our ability to meet market trends with innovative solutions and unique offers built around customer needs".

Friulchem (AIM:FCM), in the market for over 20 years, is currently one of the leading Italian CDMOs (Contract Development Manufacturing Organisation) operating in the international healthcare industry through research and development and contract manufacturing of semi-finished and finished products containing both active pharmaceutical ingredients and food supplements, with specialisation in drug delivery systems for the veterinary sector, which represents Friulchem's excellence, and in the development of generic drug technical documents for the human sector. Friulchem is an innovative SME and B2B company with a considerable inclination for end-customers. It has solid Italian roots thanks to its production plant in Vivaro (Pordenone) and its administrative headquarters in Milan. The Company, strongly oriented towards R&D activities, boasts long-standing relations with the main multinationals in the pharmaceutical sector.

ISIN Ordinary shares IT0005378457 - ISIN Warrant Friulchem 2019-2022 IT0005378366

<u>Friulchem S.p.A.</u> ir@friulchem.com Tel: +39 02 36591450

CFO SIM S.p.A. – Euronext Growth Advisor ecm@cfosim.com Tel: +39 02 30343 1

<u>CDR Communication - Investor and Media Relations</u> Silvia Di Rosa <u>silvia.dirosa @cdr-communication.it</u> Marianna Tremolada <u>marianna.tremolada @cdr-communication.it</u> Claudia Messina <u>claudia.messina @cdr-communication.it</u>